Rational Therapeutics Release: Metastatic NSCLC Survival Doubled Using Functional Profiling to Select Drug Treatments

Published: Jun 02, 2010

LONG BEACH, Calif. & CHICAGO--(BUSINESS WIRE)--A team of investigators at Rational Therapeutics, Inc. (http://www.rationaltherapeutics.com) and the Malcolm Todd Cancer Institute (Long Beach, Calif.) has reported that functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) can be used to prescribe treatment regimens that double the response rate and survival in patients with Stage IV non-small cell lung cancer (NSCLC). The findings of their phase II clinical trial will be presented on Sunday, June 6th at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Back to news